Servier and Paris Saclay Cancer Cluster Forge Stronger Partnership to Accelerate Oncology Innovation
Servier and the Paris Saclay Cancer Cluster (PSCC) are deepening their collaboration to accelerate therapeutic innovation in oncology, building on a partnership that began in 2025. The collaboration focuses on breaking down barriers between pharmaceutical companies, startups, and academic institutions to expedite the industrial development of cancer treatments.
Strategic Alignment and Shared Goals
The PSCC, a biocluster established near the Gustave Roussy Institute, aims to accelerate the industrial development of oncology innovation. Servier views collaboration with the PSCC as strategically important, with the goal of aligning objectives with the broader ecosystem and guiding investments. Nathalie de Préville, Director of Public-Private Partnerships at Servier, emphasized that the partnership differs from traditional public-private collaborations focused on pre-competitive projects, sharing a mutual commitment to accelerating therapeutic innovation as a priority of Servier’s 2030 strategy.
Open Innovation and Collaborative R&D
Servier is committed to collaborative R&D and has actively supported the PSCC ecosystem since its creation. The partnership centers on accelerating the industrialization of innovative scientific projects, with a focus on transparency and balanced exchanges between teams. Alice de Queylard, Chief Innovation Officer at PSCC, highlighted the positive impact of this transparency, noting a “true spirit of sharing” during project presentations and discussions of common challenges.
Supporting Oncology Startups
The collaboration provides significant benefits to startups within the PSCC network. These companies gain access to Servier’s expertise in areas such as clinical development, quality control, regulatory affairs, and market access strategies. Servier has already initiated programs like the “Challenge Day” to identify startups that could benefit from its expertise, leading to participation in the Spartners by Servier & BioLabs incubator and collaborative projects with Servier teams. PSCC intends to continue these initiatives.
Focus on Digital Twins and Foundation Models
Recent discussions between Servier and PSCC teams, led by Walid Kamoun (Servier’s Oncology R&D Director) and Benjamin Garel (PSCC CEO), highlighted the potential of digital twins and foundation models in oncology research. These virtual replicas of organs or tumors can simulate disease progression and support precision medicine, offering opportunities for modeling tumor biology, identifying new therapeutic targets, and creating synthetic control arms in clinical trials.
Upcoming Events and Continued Collaboration
The PSCC has a series of events planned for the spring of 2026, including webinars on innovative purchasing in hospitals (March 26), coffee breaks on colorectal cancer (March 31), and workshops on scaling tumor organoids (April 7). Servier and the PSCC are committed to continuing their collaboration and organizing future events to foster innovation in oncology.
Key Takeaways
- Servier and PSCC are strengthening their partnership to accelerate oncology innovation.
- The collaboration focuses on bridging the gap between industry, startups, and academia.
- Startups benefit from access to Servier’s expertise in key areas of pharmaceutical development.
- Digital twins and foundation models are emerging as key areas of focus for future research.
- Continued collaboration and events are planned to foster ongoing innovation.